# Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease

NCT06984484

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Not Applicable |
| **Sponsor** | Devintec Sagl |
| **Enrollment** | 208 participants |

## Key Eligibility Criteria

### Inclusion (6)

- Male and female patients, aged e 18 years and d 75 years.
- Evidence of symptomatic GERD: patients with ongoing heartburn and/or regurgitation (with or without dyspepsia symptoms of epigastric pain and/or burning) of at least mild to moderate severity or experienced during the least 7 days before starting the treatment, as assessed on a clinical basis by the Investigator.
- Patients not pre-treated with PPIs, even for problems different from GERD (e.g., gastroprotection, PPI-based triple or quadruple therapy for eradication of H. pylori), H2RAs, and/or with antiacids, alginates or medical devices made of substances (i.e., substance-based medical devices to treat GERD, gastroesophageal reflux and similar conditions) in the last week prior to screening.
- Patient has provided written informed consent after being informed of the study procedures and risks prior to any study-related events.
- Patients are able to understand and adhere to the study procedures.

... and 1 more (see full listing online)

### Exclusion (16)

- Patient with hypersensitivity to any Afluxin® or inactive control components.
- Rhinosinusitis or bronchitis.
- Patients with a:
- history and/or
- symptom profile and/or

... and 11 more (see full listing online)

## Locations (6 total)

IRCCS Policlinico San Martino, Genova, Italy
IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy
AOU Federico II di Napoli, Naples, Italy
... and 3 more locations